How it started
Background/History
Izon Science Limited is a company incorporated as Australo Ltd. on January 10, 2005, by four New Zealand-based scientists. In 2007, Hans van der Voorn became CEO, and on November 17, 2008, the company was renamed Izon Science Limited. Initially focused on developing tunable resistive pulse sensing instruments for nanoparticle characterization, the company later expanded into developing tools for isolating exosomes and other extracellular vesicles from biological fluids. Presently, Izon Science develops and manufactures tools for nanoparticle characterization and separation, catering to academic researchers and diagnostics companies working with extracellular vesicles, as well as those involved in nanomedicine, viruses, and virus-like particles.
The Exoid is one of Izon's latest tunable resistive pulse sensing instruments, succeeding the qViro-X, qMicro, and qNano. In June 2021, Izon Science relocated its headquarters from Burnside (Christchurch) to a larger facility on Show Place, Addington (Christchurch). The company currently employs approximately 70 individuals.
Izon has received investment funds from Bolton Equities, a privately funded investor group based in New Zealand. Research partnerships include the University Medical Center Utrecht and the VU University Medical Center in the Netherlands, the Mayo Clinic, the National Institutes of Health, and Massachusetts General Hospital.
From Wikipedia’s article on Izon Science, shared under CC BY-SA 4.0.2